Integrated Bioinformatics and Experimental Analysis Identified TRIM28 a Potential Prognostic Biomarker and Correlated with Immune Infiltrates in Liver Hepatocellular Carcinoma

This research investigates the role of Tripartite Motif-Containing 28 (TRIM28) in liver hepatocellular carcinoma (LIHC). TRIM28 expression, its prognostic value, and its impact on the immune system in LIHC patients are being investigated. The study uses data from The Cancer Genome Atlas (TCGA) to analyze TRIM28 expression, clinicopathological information, gene enrichment, and immune infiltration. R language was used for statistical analysis. The results are validated using GEPIA, ROC analysis, and immunohistochemical staining pictures from the THPA. The study concludes that TRIM28 sheds new light on LIHC mechanisms and can be an effective diagnostic and intervention tool.

• 1
  High TRIM28 expression level was associated with T classification, pathologic stage, histologic grade, and serum AFP levels.
• 2
  In patients with LIHC, TRIM28 was an independent risk factor for a poor prognosis.
• 3
  The pathways ligand-receptor interaction, which is critical in LIHC patients, were closely associated with TRIM28 expression, and the function of DC could be suppressed by overexpression of TRIM28.